Vir Biotechnology (VIR)
(Delayed Data from NSDQ)
$5.03 USD
-0.04 (-0.79%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $5.02 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VIR 5.03 -0.04(-0.79%)
Will VIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VIR
GSK Beats on Q2 Earnings & Sales, Stock Gains on '25 Outlook Raise
Vir Biotechnology, Inc. (VIR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
VIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Vir Biotechnology (VIR) Soars 11.9%: Is Further Upside Left in the Stock?
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates
GSK Q1 Earnings Beat, Sales Lag, Stock Gains on Tariff Reassurance
Other News for VIR
Vir Biotechnology (VIR) Begins Phase 3 Trial for Hepatitis Delta Treatment
Vir Biotechnology enrolls first patient in ECLIPSE trial
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program ...
Vir Biotechnology (VIR) Begins Phase 1 Trial for New Cancer Treatment | VIR Stock News
Vir Biotechnology doses first patient in VIR-5525 trial